glucocorticoid-free era for polymyalgia rheumatica: are we on the brink of change?
In The Lancet Rheumatology, Alain Saraux and colleagues' Article on the BACHELOR trial,2 a randomised, double-blind, placebo-controlled study, reports impressive results on the use of baricitinib, a Janus kinase (JAK) inhibitor, to treat recent-onset polymyalgia rheumatica without the use of oral glucocorticoids
In The Lancet Rheumatology, Alain Saraux and colleagues' Article on the BACHELOR trial,2 a randomised, double-blind, placebo-controlled study, reports impressive results on the use of baricitinib, a Janus kinase (JAK) inhibitor, to treat recent-onset polymyalgia rheumatica without the use of oral glucocorticoids